Pulse dose of oral itraconazole is effective in the treatment of onychomycosis
Keywords:
Pulse dose, oral itraconazole, onychomycosisAbstract
Background Onychomycosis is a recalcitrant disease of the nails caused by dermatophytes, yeasts, and molds. Objective To see the efficacy of pulse dose of oral itraconazole in the treatment of onychomycosis. Patients and methods It was an open clinical trial which was carried out for a period of 2 years from March 2009 to February 2011, in the outpatient department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka. Bangladesh. Thirty patients with onychomycosis were recruited purposively. 30 patients of onychomycosis were treated with oral itraconazole 400 mg/day, seven days a month for three months. Results Mean age of the respondents was 36.57±14.01 years and male to female ratio was 1:1. Among the patients, 36.7% cases had involvement of toenails and 63.3% cases had involvement of fingernails. In 6.7% cases onychomycosis was mild, 80.0% cases moderate and in 13.3% cases severe. Three months after treatment with itraconazole, improvement was found in 66.7% cases and marked improvement in 33.3%. Before treatment, culture was found positive in 30% cases and three months after treatment, culture became negative in 66.7% cases. Conclusions Monthly one week cycle of oral itraconazole 400 mg daily for 3 months is effective therapeutic option for onychomycosis.References
Andrew J, Achten G. Onychomycosis. Int J Dermatol 1987; 26:481-90.
Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126(Suppl 39): 23-7.
Summerbell RC. Epidemiology and ecology of onychomycosis. Dermatology 1997; 94: 32-6.
Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994; 31:21-5.
Faergemann J, Anderson C, Hersle K et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750-3.
Gupta AK, Scher RK, De Doncker P. Current management of onychomycosis. An overview. Dermatol Clin 1997; 15: 121-35.
Arenas RJ. Dominguez-Cherit, Fernandez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995; 34: 138-43.
Scher RK. Diseases of the nails. In: Conn H, ed. Current Therapy. Philadelphia: WB Saunders; 1990. P. 736–42
Elewski BE. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993; 28: S28-34.
Cauwenbergh G, Degreef H, Heykants I et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am. Acad. Dermatol 1988; 18: 263-8.
Heikkala H, Stubbs S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699-701.
Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio. Arch Dermatol 1997; 133: 1172-3.
Mishra M, Panda P, Tripathy S et al. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol 2005; 71: 262-6.
De Doncker P, Decroix J, Pierard PE et al. Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996; 132: 34-41.
Odom RB, Aly R, Scher KR et al. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol 1997; 36: 231-5.
De Backer, Keyser PD, Vroey CD, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis terbinafine 250mg/day vs. itraconazole 200mg/day—a double-blind comparative trial. Br J Dermatol 1996; 134 (Suppl. 46), 16-7.
Wu J, Wen H, Liao W. Small-dose itraconazole pulse therapy in the treatment of onychomycosis. Mycoses 1997; 40: 397-400.
